Regulus Therapeutics (NASDAQ:RGLS) Upgraded at StockNews.com

StockNews.com upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) to a sell rating in a research report released on Tuesday.

A number of other research firms also recently weighed in on RGLS. Canaccord Genuity Group raised their price target on Regulus Therapeutics from $11.00 to $28.00 and gave the company a buy rating in a research report on Tuesday, June 25th. Oppenheimer restated an outperform rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Finally, HC Wainwright restated a buy rating and set a $10.00 price target on shares of Regulus Therapeutics in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and an average target price of $10.80.

Regulus Therapeutics Price Performance

NASDAQ:RGLS opened at $1.71 on Tuesday. Regulus Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.79. The stock has a fifty day moving average of $1.64 and a 200 day moving average of $2.04.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.17). Equities analysts predict that Regulus Therapeutics will post -0.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 453,784 shares during the period. CVI Holdings LLC purchased a new position in shares of Regulus Therapeutics in the first quarter worth about $4,050,000. Victory Capital Management Inc. increased its holdings in Regulus Therapeutics by 16.5% during the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock valued at $348,000 after purchasing an additional 38,529 shares during the period. Renaissance Technologies LLC increased its holdings in Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 42,600 shares during the period. Finally, Rhumbline Advisers purchased a new position in Regulus Therapeutics during the 2nd quarter valued at about $136,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.